A review of chemical agents in the pharmacotherapy of addiction.
Current medicinal chemistry October 1, 2002 DOI: 10.2174/0929867023368980 via PubMed
Summary
AI-generated from the abstractIbogaine, a naturally occurring alkaloid, has been reported to interrupt cravings for alcohol, cocaine, and opiates. Other alkaloids from Tabernanthe iboga, such as ibogamine and tabernanthine, offer insights into structure-activity relationships at receptors involved in addiction. The synthetic congener 18-MC shows potential as an anti-addictive agent without ibogaine's hallucinogenic effects. Acamprosate, BP 897, GBR12909, lofexidine, and memantine have also shown promising results. Currently, no drugs are approved in the U.S. for treating addictions to cocaine, methamphetamine, other stimulants, or PCP.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Addiction Ibogaine |
| Keywords | Anti-addiction medications Substance abuse treatment Drug treatment Craving reduction Addiction therapy |
| Citations | 70 |
| Key finding | Ibogaine and several other compounds show promise as anti-addictive agents, but no drugs are currently approved in the U.S. for stimulant or PCP addiction. |
Abstract
Chemical substance abuse has tormented mankind throughout history. A number of chemical approaches have been employed in an attempt to treat chemical addiction. Unfortunately, most of these have proven unsuccessful though several chemical entities have been shown to be moderately effective. The naturally occurring alkaloid ibogaine has been reported to interrupt the cravings for alcohol, cocaine and opiates. Other alkaloids from Tabernanthe iboga, such as ibogamine and tabernanthine, provide insight into the structure activity relationship at the different receptors believed to be involved in addiction. The synthetic iboga alkaloid congener, 18-MC, also shows potential as an anti-addictive agent without the hallucinogenic effects of ibogaine. Additionally, acamprosate, BP 897, GBR12909, lofexidine and memantine have shown promising results in the treatment of addiction. All of these leads provide a start for the medicinal chemist to design anti-addictive agents, since currently no drugs are approved in the U.S. for the treatment of addictions to cocaine, methamphetamine, other stimulants or PCP.